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1. Introduction 
In spite of the fact that the hyperlipidaemia of pregnancy is usually considered 
physiological [1-12], all pregnant women develop hypertriglyceridaemia with subsequent 
formation of small, dense low-density lipoprotein(LDL) particles, both of which are an 
independent risk factor of coronary heart disease(CHD) [13]. By 3rd trimester most women 
have a lipid profile which could be considered highly atherogenic in the nonpregnant state 
[14]. Similarly, animal model studies showed that maternal hypercholesterolaemia during 
pregnancy even when temporary and limited to pregnancy triggers pathogenic events in the 
fetal aorta, greatly enhanced atherogenesis later in life[14, 15]. On the other hand, 
intrauterine growth retardation (IUGR) has been associated with pre-eclampsia [16], as a 
result of decreased maternal lipid transfer to the fetus secondary to placental abnormalities. 
IUGR has also been associated with failure of development of hyperlipidaemia during 
pregnancy with subsequent reduction in maternal lipid reaching the fetus in a normal 
placenta [17, 18]. Generally, serum lipid and lipoprotein levels in pregnancy are modulated 
by complex interactions between genetics, medical complications of pregnancy, co-existing 
medical conditions, and other maternal factors [9, 19]. This underscores the need to take a 
meticulous and decisive approach in interpreting hyperlipidaemia of pregnancy. In 
searching for an emergent or new cardiovascular risk factor, concerning lipid and 
lipoprotein in adult males and nonpregnant women, several lipoprotein ratios or 
atherogenic indices have been defined[20]. These ratios were found to provide information 
on risk factors difficult to quantify by routine analyses and could be a better mirror of the 
metabolic and clinical interactions between lipid fractions[21]. Despite findings of [22] in a 
registry study of heterozygous familial hypercholesterolaemia(FH) mothers, who observed 
no significant untoward effect of lipid-lowering drugs during pregnancy, the current trend 
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is that Statins, classified by FDA as category X, should be avoided in pregnancy[23, 24]. The 
use of lipid and lipoprotein ratios in interpreting pregnancy associated hyperlipidaemia 
may provide a balanced hyperlipidaemia not only in normal pregnancy but also in the other 
modulators of lipid metabolism in pregnancy. 
2. Pathophysiology of hyperlipidaemia of pregnancy 
Pregnancy is a dynamic state consequent of the fact that normal fetal development needs 
the availability of essential nutrients such as glucose, free fatty acids(FFAs), long-chain 
polyunsaturated fatty acids(LCPUFAs), amino acids, minerals, vitamins, to be continuously 
supplied to the growing fetus despite intermittent maternal food intake[10,25]. The 
dynamism of the gestational period support fetal growth and development while 
maintaining maternal homeostasis and preparation for lactation. This is achieved by 
complex and continuously evolving adjustments in maternal nutrient metabolism occurring 
throughout gestation. 
Many of these maternal adjustments occur in the early stages of pregnancy when the fetus is 
too small to make considerable metabolic demands of the mother, resulting in the maternal 
metabolism working from a different baseline compared with the nonpregnant state. This 
period is called the anabolic phase. In late pregnancy, however, the maternal metabolic 
processes become more complicated because of the two-way interaction between the mother 
and the developing fetus. This is caked the catabolic phase. 
The changes in nutrient metabolism can be described by several general concepts[8]: (a) 
adjustments in nutrient metabolism are driven by hormonal changes, fetal demands and 
maternal nutrient supply; (b) more than one potential adjustment exists for each 
nutrient; (c) maternal behavioural changes augment physiologic adjustment; and (d) a 
limit exists in the physiologic capacity to adjust nutrient metabolism to meet pregnancy 
needs, which when exceeded, fetal growth and development are impaired. Subsequently, 
metabolic adaptations, during pregnancy are essential [26]: 1, To ensure adequate 
growth and development of the fetus; 2, to provide the fetus with adequate energy stores 
and substrates that are needed following birth; 3, and, to provide the mother with 
sufficient energy stores and substrates to cope with the demands of pregnancy as well as 
those of labour and lactation. One of the maternal metabolic adjustments during 
pregnancy includes accumulation of fat depots in maternal tissues[26]. During this 
anabolic phase, the number of insulin receptors on the adipocytes increases, culminating 
into increased insulin sensitivity, increase lipoprotein lipase(LPL) activity which 
hydrolyses circulating triglycerides for tissue uptake, enhanced lipogenesis and marked 
maternal fat deposition(about 3.5 to 6.0kg) which is used as energy sources for the 
mother so that glucose is spared for the developing fetus in the catabolic part of the 
pregnancy[27, 28]. Lean women increase their fat stores more than obese women per kg 
body weight, likely due to higher insulin sensitivity in them, in early pregnancy, 
promoting lipid uptake and de novo synthesis. 
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The important attributes of fat deposits during the anabolic phase in pregnant women are 
:(1) Hyperphagia, present in pregnant women and increases as gestational time advances. 
This progressive increase in the availability of exogenous substrates actively contributes to 
maternal accumulation of fat depots [29]; (2) Promotion of lipogenesis and suppression of 
lipolysis mediated by progressive increase in insulin and its sensitivity and enhanced by 
progesterone and cortisol [30]; (3) The proportional increase in adipose tissue lipoprotein 
lipase (LPL) activity [1,12,31) which hydrolyzes triglycerides(TGs) in form of TG-rich 
lipoproteins, chylomicron and very-low density lipoprotein(VLDL), which are respectively 
converted into remnant particles and intermediate-density lipoprotein (IDL). The hydrolytic 
products, non-esterified fatty acids(NEFA) and glycerol, are partially taken up by subjacent 
tissues [11, 12, 32, 33); (4) the unique capacity of tissue to utilize intracellularly the glycerol 
released during lipolysis. Under normal circumstances, the negligible glycerol kinase 
activity in adipose tissues hampers the utilization of glycerol for glycerol-3-phosphate 
synthesis and its use for the synthesis of TGs [34,35]. However, an increase in glycerol 
kinase activity and its subsequent capacity to metabolize glycerol has been found in rodents 
under condition of hyperinsulinaemia and enhanced fat accumulation, such as occurs in 
obesity [35, 36]. The lower lipolytic activity together with the augmented capacity of the 
tissues for the synthesis of glycerol-3-phosphate for uses in TG synthesis from both glucose 
and intracellular released glycerol results in net intracellular accumulations of TGs. Since all 
these pathways are stimulated by insulin, it is proposed that the enhanced insulin 
responsiveness [37] in the presence of an augmented response of the pancreatic β-cells to the 
insulinotropic stimulus of glucose that has been found in early pregnant women [38] would 
be the principal driving forces for the net fat depot accumulation at this stage of pregnancy. 
These ultimately lead to maternal fat accumulations in the anabolic phase of gestation. 
The anabolic condition of adipose tissue during early pregnancy switches to a net catabolic 
state during the last 1/3 of gestation. The signals responsible for this switch from lipid 
storage to lipid mobilization are not well understood; however, placental hormones that 
increase with advancing gestation, known to induce maternal insulin resistance, may play a 
major role. Placental growth hormone, human placental lactogen, leptin, and tumour 
necrosis factor-α(TNF-α) are placental hormones that induce insulin resistance. The 
presence of high plasma levels of placental hormones, known to have lipolytic effects, 
human placental lipase (HPL), an augmented production of catecholamine secondary to 
maternal hypoglycemia [38], and the insulin-resistant condition present at this stage [39, 40], 
appear to be responsible for the net breakdown of maternal fat depots, consistently causing 
increments of plasma nonesterified fatty acids(NEFA) and glycerol levels during the 3rd 
trimester of gestation. The main destination of these lipolytic products released from 
maternal adipose tissue is the maternal liver. They are converted in the liver into their 
respective active forms, acyl-CoA and glycerol-3-phosphate, to become partially re-
esterified for the synthesis of triglycerides, which are transferred to native VLDL particles 
and released into the circulation. Acyl-CoA can also be converted throughout the β-
oxidation pathway to acetyl-CoA for energy production and ketone body synthesis, whereas 
glycerol may also be used for glucose synthesis.  Fetal-placental glucose and amino acids 
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utilization rates are highest at 22 to 26weeks decreasing near term. In contrast lipid transport 
is maximal in the 3rd trimester coincident with rapid fetal fat accretion, this spares the 
mother to utilize glucose during this period. Humans are born with the highest percentage 
of fat (12 to 15%) compared to any species and 90% deposition occurs in the last 10weeks of 
gestation, exponentially increasing to 7g/day near term. The preferential use of glycerol 
released from maternal adipose tissue for gluconeogenesis acquire greater importance 
during maternal fasting period, when circulating glucose levels are lower than under 
nonpregnant conditions[34]. Under fed condition in early gestation, plasma ketone body 
values are even lower in pregnant than in nonpregnant condition [41], indicating an 
enhanced use of these fuels by maternal tissues as alternative substrate to glucose. However, 
during fasting period maternal ketogenesis become highly accelerated, as indicated by the 
exaggerated increase in plasma ketone bodies that occur [41]. This benefit the fetus in two 
ways: (1) ketone bodies are used by maternal tissues, thus, saving glucose for essential 
function and delivery to the fetus, (2) placental transfer of ketone bodies is very efficient, 
attaining the same concentration in fetal plasma as in maternal circulation[42]. In addition, 
ketone bodies may be used by the fetus as oxidative fuels as well as substrate for brain lipid 
synthesis [43]. 
Insulin is well known to inhibits adipose tissue lipolytic activity, hepatic gluconeogenesis 
and ketogenesis but to increases adipose tissue LPL activity. Thus, it is not surprising that 
all of these pathways change in the opposite direction which is consistent with insulin 
resistance occurring in later part of pregnancy. These pathways become even further 
modified under uncontrolled gestational diabetes mellitus(GDM), where insulin resistance 
is further enhanced [44]. 
3. Maternal hyperlipidaemia of pregnancy 
The enhanced net breakdown of fat depots during late pregnancy is associated with 
hyperlipidaemia, which chiefly corresponds to plasma rises in TGs with smaller rise in 
phospholipids and cholesterol [44]. The greatest increased in plasma TGs corresponds to 
VLDL values but TGs also accumulates in other lipoprotein fractions, which do not 
normally transport them, such as LDL and HDL [45]. The high TGs concentration secondary 
to lipolysis in the presence of increased cholesteryl ester transfer protein(CETP) activity, 
occurring in midgestation[45], contributes to the accumulation of TGs in the lipoprotein 
fractions of higher densities, LDL and HDL[44, 45]. CETP facilitates the exchange of TGs by 
esterified cholesterol between VLDL and either LDL or HDL. Furthermore, during late 
gestation the activity of hepatic lipase (HL) greatly decreased [45]. HL converts the buoyant 
HDL-2-TG-rich particles into small HDL-3-TG-poor particle allowing a proportional 
accumulation of buoyant HDL-2-TG-rich particle. 
Other hormonal dynamism occurring during pregnancy contributing to maternal 
hypertriglyceridaemia are, table 1, consistently increasing oestrogen concentration almost 
throughout the gestation period and oestrogen has been shown to (1) increase endogenous 
production of VLDL-TGs [46]; (2) reduce adipose tissue LPL activity [33, 45], and (3) inhibition 
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of hepatic TG lipase activity [33, 44]. Thus, the oestrogenic influence over TG metabolism 
suggests an increased circulating VLDL-TG. Although the role of progesterone in TG 
metabolism is not certain, its administration in rats had a lipid neutral effect. Thus, the 
interaction between oestrogen and progesterone would favour hypertriglyceridaemia. Prolactin 
may inhibit adipose tissue LPL while stimulating breast LPL in late gestation [45]. Thus, the 
physiologic outcome of increasing concentration of Prolactin with advancing pregnancy would 
be a shift in storage from the adipocytes to the breast in preparation for lactation. 
 
Enzymes Activities  
Adipose tissue lipoprotein lipase(LPL) decrease  
Diacylglycerol acetyltransferase decrease  
Cholesterol 7-alpha hydroxylase decrease  
Placental lipoprotein lipase (PLPL) increase  
Placental triglycerides hydroxylase Increase  
Phospholipase A2(PLA2) Increase  
Cholesterol ester transfer protein(CETP) Increase  
Hepatic lipase Decrease  
  
Hormones and cytokines Concentrations  
Estradiol Increase  
Insulin 
Sensitivities increase during first 
trimester but subsequently 
decreases from second trimester to 
end of gestation
 
Human placental lactogen Increase  
Prolactin Increase  
Cortisol Increase  
Glucagon Increase  
Porgesterone Increase  
Leptin Increase  
Tumor Necrosis Factor-alpha(TNF-alpha) Increase  
Human chorionic somatomammotropin(HCS) Increase  
Table 1. Hormone and enzyme changes during the course of pregnancy. 
The combined effects of enhanced liver production of VLDL [47, 48], decreased removal of 
these particles from the circulation due to low LPL activity [45,49], high CETP activity and 
low HL activity, would not only be responsible for the accumulation of TGs in LDL but also 
for the proportional accumulation of TG in buoyant TG-rich HDL-2b subfractions at the 
expense of the cholesterol-rich and TG-poor HDL-2a or HDL-3[45]. 
The increasing insulin-resistance in late gestation and continuously increasing plasma 
oestrogen levels occurring during pregnancy are the main hormonal factors responsible for 
these metabolic changes resulting into the development of maternal hypertriglyceridaemia, 
see table 2.  
 










HDL-C 67±12 83±19 81±17 69±10 
LDL-C 90±17 130±46 136±33 99±23 
TGs 79±27 151±80 245±73 77±34 
TC 173±18 243±53 267±30 183±23 
ApoA-1 170±27 204±22 196±28 163±24 
ApoA-2 49±7 52±6 49±5 47±6 
ApoB 70±21 91±25 113±29 61±22 
ApoC-11 265±13 299±18 314±21 237±11 
ApoC-111 141±3 188±5 217±6 121±19 
ApoE 41±12 42±9 49±19 42±20 
Lp(a) 60(0-1440) 63(2-1210) 54(0-1230 86(11-473) 
VLDL-1 19(12-55) 47(26-110) 109(38-170) 23(5-85) 
VLDL-2 17(7-45) 36(20-77) 103946-168) 23(13-44) 
IDL 26(13-54) 58(24-100) 124(79-157) 35(18-62) 
Total LDL 200(135-323) 292(206-410) 353(244-534) 207(150-363) 
LDL-1 33(16-52) 49(37-70) 67(27-96) 50(22-130) 
LDL-11 143(95-231) 160(103-287) 201(59-316) 135(72-258 
LDL-111 28(15-56) 32(24-165) 123(43-192) 31(5-68) 
Table 2. The increasing lipid and lipoproteins during course of gestation(courtesy: Ahmet Basaran, 
MD) 
4. Placental transfer of maternal lipid and lipoproteins and their 
metabolites to the fetus 
The human placenta contains VLDL, LDL, HDL, and scavenger receptors as well as LDL 
receptor-related proteins. The placenta also has LPL, phospholipase-A2 (PLA-2) and 
intracellular lipase activities as well as plasma membrane fatty acid-binding protein 
(FABP/GOT2), fatty acid translocase (CD36), fatty acid transfer protein (FATP) and different 
cytoplasmic FABPs [29, 42,50, 51]. Thus, lipid and lipoproteins in maternal plasma can be 
taken up and handled by the placenta, allowing LCPUFAs associated with plasma 
lipoproteins to be transferred to the fetus. The human placenta is capable of transporting 
free fatty acids(FFAs) by diffusion and selectively increases the transport of essential fatty 
acids (EFAs) and their long-chain polyunsaturated fatty acids (LCPUFA) derivatives by 
fatty acid carrier proteins.  
Although lipoprotein TGs does not directly cross the placental barrier, the placenta has 
mechanisms to release fatty acids(FAs) circulating in maternal plasma lipoproteins into the 
fetus. In addition, high levels of TGs in maternal circulation may create a steep 
concentration gradient across the placenta, which accelerates their transport and deposition 
in fetal tissues. In term human trophoblasts, insulin and fatty acids have been shown to 
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enhance the expression of adipophylin, which is associated with cellular lipid droplets and 
implicated in cellular fatty acid uptake and storage of neutral lipids 
4.1. Fatty acids transfer 
The supply of LCPUFA is important for fetal growth and tissue development especially for 
the development of the nervous system and the considerable requirements of these 
LCPUFAs in the fetus must be provided by their placental transfer [52]. The plasma 
membrane fatty acid-binding proteins present in human placental membrane [51,52] are 
responsible for the preferential uptake of LCPUFAs. A selective cellular membrane of 
certain FAs may also contributes to the placental transfer process, as would the conversion 
of a certain proportion of arachidonic acid(AA) to prostaglandins(PGs)[52], the 
incorporation of some FAs into phospholipids[50-52], the oxidation of placental fatty 
acids[53] and the synthesis of FAs[52,53]. Even though essential fatty acids(EFA) as well as 
LCPUFAs are transferred across the placenta, the fetus needs to receive substantial amounts 
of preformed AA and docosahexaenoic acid(DHA) which can be synthesized to a limited 
extent from the EFA. The two dietary EFAs are linoeic acid(18:2ω-6) and α-linolenic 
acid(18:3ω-3), which are precursors of the ω-6 and ω-3 LCPUFA, respectively. The synthesis 
of AA and DHA do not take place in the fetus or the placenta in substantial amounts, owing 
to the low activities of the desaturating enzymes. Both AA and DHA are abundant in the 
brain and the retina and their appropriate supply during pregnancy and the neonatal period 
is critical for proper function [1,54]. Maternal plasma NEFA, though in smaller proportion 
than lipoprotein TGs, is an important source of polyunsaturated fatty acids(PUFAs) for the 
fetus [51,52]. Maternal plasma NEFAs correlates with those in the fetus and maternal 
adipocytokines have been associated with fetal growth[1]. The combination of these 
processes determines the actual rate of placental FAs transfer and its selectivity, consequent 
to the proportional enrichment of certain LCPUFAs, such as AA and DHA in fetal as 
compared with maternal compartments [52, 54].  
4.2. Cholesterols 
Cholesterol plays a key role in embryonic and fetal development hence the demands for 
cholesterol in the embryo and fetus is relatively high. Cholesterol is an essential component 
of cell membrane influencing the fluidity and passive permeability by interacting with 
phospholipids and sphingolipids [55]. It’s the precursor of bile acids and steroid hormones. 
It is also required for cell proliferation and development of the growing body, cell 
differentiation, and cell-to-cell communications, and is the precursor of oxysterol, which 
regulates key metabolic processes. Available cholesterol in fetus is contributed by: (1) 
transfer from the mother especially during the first half of the gestation and too little 
cholesterol due to lack of maternal cholesterol or reduced expressions of placental 
lipoprotein receptors is correlated with small fetuses and a trends for microcephally; and (2) 
Fetal synthesis especially during the last half of gestation. Too little cholesterol due to lack of 
synthesis leads to a spectrum of congenital defects as seen in infants with Smith-Lomli-
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Opitz Syndrome(SLOS) who are unable to synthesize cholesterol at normal rate due to 
null/null mutations in 3β-hydroxysteriod Δ7-reductase, the enzyme that converts 7-
dehydrocholesterol to cholesterol. The placental endothelial cells are capable of transporting 
substantial amounts of cholesterol to the fetal circulation and this mechanism is further 
enhanced by liver-X receptors and induced up regulation of ATP-binding cassette 
transporter, ABCA1 and ABCG1[56].  
4.3. Glycerol 
Maternal Plasma glycerol levels are consistently elevated during late pregnancy, but crosses 
the placenta less than glucose or L-alanine [1,25, 57] though they all have similar molecular 
weights. Transfer of maternal glycerol via the placenta is by simple diffusion (2). However, 
its effective and rapid utilization through other pathways, such as gluconeogenesis and 
glyceride glycerol synthesis in the mother[10,25] results in its low plasma concentration and 
this very active kinetics impede the formation of the adequate gradient to create the 
appropriate driving forces for its placental transfer. 
4.4. Ketone bodies 
In the 3rd trimester of pregnancy, under fed conditions, plasma ketone body concentrations 
remain low although are greatly increase compared to nonpregnant condition under fasting 
[58] consequent to enhanced adipose tissue lipolysis. The lipolysis accelerates delivery of 
NEFA to the liver and enhanced ketogenesis. Ketone bodies can easily cross the placenta 
and be used as fuels and lipogenic substrates by the fetus. The transfer of ketone bodies 
across the placenta occurs either by simple diffusion or by a low-specificity carrier-mediated 
process [25]. The activities of ketone body metabolizing enzyme are present in fetal tissues 
(brain, liver and kidneys)[1,25] and can be increased by conditions of maternal ketonaemia 
such as occurs in starvation, during late pregnancy[39] or high-fat feeding[25]. Ketone 
bodies are used by the fetus as oxidative fuels as well as substrates for brain lipid synthesis 
[25]. However, in maternal hyperketonaemia as occurs in poorly controlled diabetes patients 
associated with transfer of excessive arrival of ketone bodies to the fetus seems to be 
responsible for the major damages [10], increasing stillbirth rate, incidence of 
malformations, and impaired neurophysiologic development [10]. Subsequently, it could be 
recommended that pregnant mothers, if possible, should avoid starvation and high fat diet 
especially in the 3rd trimester. 
5. The importance of lipid and lipoprotein ratios in hyperlipidaemia in 
adult male and nonpregnant females 
While cholesterol is a key component of the development of atherosclerosis, LDL-C 
concentration has been the prime index of cardiovascular disease(CVD) risk and the main 
target for therapy[21]. However, currently, there is almost unanimous agreement among 
epidemiologists and clinicians that coronary risk assessment based exclusively on LDL-C is 
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not optimal[59]. Therefore in the recent past, efforts have been made in seeking emergent or 
new cardiovascular risk factors to improve cardiovascular disease prediction[20] and in an 
attempt to optimize the predictive capacity of lipid profile, several lipoprotein ratios or 
“atherogenic indices” have been defined. In the Framingham study, the TC:HDL-C ratio, a 
useful summary of the joint contribution of total cholesterol(TC) and HDL-C to coronary 
heart disease(CHD) risk[60], was also found to be an excellent predictor of CHD risk, with a 
hazard ratio of 1.21 for a 1.0 increment in ratio[60]. The value of this ratio should be 
emphasized when lipid profile is within desirable range. It was shown that patients with 
high-risk LDL-C levels >160mg/dl(4.2mmol/L) and low TC: HDL-C ratio (≤5.0) had an 
incidence of CHD of 4.9%. This was similar to those with low levels of both LDL-
C(≤130mg/dl, 3.4mmol/L) and TC:HDL-C ratios, 4.6%[60]. By contrast, subjects with low-
risk LDL-C levels(≤130mg/dl, 3.4mmol/L) and high TC:HDL-C ratio(>5.0) had a 2.5-fold 
higher incidence of CHD than those with similar LDL-C levels but low TC:HDL-C ratio[60]. 
For example, TC of 231mg/dl(5.89mmol/L) and HDL-C of 42mg/dl(1.09mmol/L) gives a 
TC:HDL-C ratio of 5.5, which indicate moderate atherogenic risk[61]. On the other hand, 
with the same level of TC, if HDL-C were 60mg/dl(1.55mmol/L), the ratio would be 3.8[61]. 
However, in the Helsinki Heart Study[62], it was demonstrated that the LDL-C:HDL-C ratio 
that paints the most relevant picture of a person’s cardiovascular health risk especially when 
triglyceridaemia is taken into account and the risk is significantly higher in the presence of 
hypertriglyceridaemia. When there is no reliable calculation of LDL-C, especially when 
triglyceridaemia exceeds 300mg/dl(3.36mmol/L), it is preferable to use the TC:HDL-C ratio. 
Similarly individuals with high concentration of triglycerides, VLDL fraction shows 
cholesterol enrichment and thus the LDL-C:HDL-C ratio may underestimate the magnitude 
of the lipoprotein abnormalities in them[21]. Subsequently, both TC:HDL-C, known as the 
atherogenic or Castelli index, and LDL-C:HDL-C ratios are two important components and 
indicators of vascular risk, the predictive values of which is greater than isolated parameters 
used  independently, particularly LDL-C. These ratios can provide information on risk 
factors difficult to quantify by routine analyses and could be a better mirror of the metabolic 
and clinical interactions between lipid fractions. Their applications therefore in interpreting 
hyperlipidaemia of pregnancy cannot be over emphasized. 
5.1. ApoB:ApoA-1 ratio 
Apolipoprotein-B(apoB) represents most of the protein contents in LDL and is also present 
in IDL and VLDL. ApoA-1 is the principal apolipoprotein in HDL and is believed to be a 
more reliable parameter for measuring HDL than cholesterol content since it is not subject to 
variation. Therefore, the apoB:apoA-1 ratio is also  highly valuable for detecting atherogenic 
risk, and there is currently sufficient evidence to demonstrate that it is better for estimating 
vascular risk than the TC:HDL-C ratio[63-65]. The apoB:apoA-1 ratio was found to be 
stronger than the TC:HDL and LDL:HDL ratios in predicting risk[63]. ApoB:ApoA-1 ratio 
reflects the balance between two completely opposite processes. Transport of cholesterol to 
peripheral tissues, with its subsequent arterial internalization, and reverse transport to the 
liver[66]. Consequently, a larger ratio will implies higher amount of cholesterol from 
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atherogenic lipoprotein circulating through the plasma compartment and likely to induce 
endothelial dysfunction and trigger the atherogenic process. On the other hand, a lower 
ratio will indicate less vascular aggression by plasma cholesterol and increased more 
effective reverse transport of cholesterol, as well as other beneficial effects, thereby reducing 
the risk of CVD. However, its use is limited by the fact that apolipoprotein measurement 
methods are not widely used as lipoprotein methods 
5.2. TG:HDL ratio 
Known as the atherogenic plasma index shows a positive correlation with HDL-C 
estimation rate(FERHDL) and an inverse correlation with LDL size[67]. Therefore, the 
phenotype of LDL and HDL particles is clearly synchronized with the FERHDL. The 
simultaneous use of TG and HDL in this ratio reflects the complex interaction of lipoprotein 
metabolism overall and can be useful for predicting plasma atherogenecity especially in 
pregnant women who manifesting with hypertriglyceridaemia of pregnancy. An 
atherogenic plasma index[Log(TGs:HDL)] over 0.5 has been proposed as the cutoff point 
indicating atherogenic risk[67]. 
5.3. LDL-C:apoB ratio 
Although apoB is not an apolipoprotein exclusive to LDL, since it is present in other 
atherogenic lipoproteins such as IDL and VLDL, the LDL:apoB ratio provides approximate 
information on LDL particle size. A ratio of <1.3 indicate the predominance of LDL particle 
with low cholesterol content, consistent with small, dense LDL particle[68].  
Variations in plasma lipid and lipoprotein ratios in adult men and nonpregnant women 
have been associated with more substantial alterations in metabolic indices predictive of 
future consequences of hyperlipidaemia than individual components of plasma lipid profile 
alone[69, 70] and as discussed above. Given the physiological role of gestational 
hyperlipidaemia in fetal development and the fact that the adaptations in maternal lipid 
metabolisms taking place throughout gestation is not without consequences, an urgent 
establishment of reference values for lipid and lipoprotein ratios in normal pregnancy is 
highly recommended.   
5.4. The hyperlipidaemia of pregnancy, a dyslipidaemia? Find out! 
5.4.1. The importance of lipid and lipoprotein ratios in interpreting the hyperlipidaemia of 
pregnancy 
In normal nonpregnant adult population, higher concentrations of plasma triglycerides are 
associated with preferentially higher VLDL-1 concentration [71]. This particle is secreted by 
the liver to supply tissues with TGs fatty acids in the post absorptive state. The 
concentration of VLDL-2, the principal precursor in the circulation to IDL and LDL, does not 
change as dramatically. In addition, in normal nonpregnant adult population, a higher 
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concentration of VLDL-1 is associated with a failure of insulin action and increased risk of 
CHD. In contrast, in pregnant women, as pregnancy progresses and high TG levels 
developed, VLDL-1 and VLDL-2 rose together so that the ratio, instead of increasing 2-fold, 
as would be predicted from population studies in the nonpregnant subjects (VLDL-1 o 
VLDL-2 ratio at a plasma TGs of 0.5mmol/L is 1.0 compared to 2.0 at plasma TGs of 
2.5mmol/L)[71], remain constant. Sattar[33], et al, found a parallel increase in the small 
cholesterol-rich VLDL-2(17 to 103mg/dl) and the larger TG-rich VLDL-1(19 to 109mg/dl) at 
35 weeks. Similarly, the relationships of VLDL constituents expressed as ratios were not 
significantly different comparing antepartum and postpartum observations, however, the 
TG/C ratio was higher at all of these times compared to controls, but the composition of 
these fractions was similar to that seen in a recent cross-sectional survey of healthy adults 
(19). The increase in VLDL-TG during gestation is likely due to an increase in VLDL 
synthesis rather to a compositional change in the VLDL particle, as a study showed no 
significant increase in VLDL TG/C ratio over time, and the ratios is similarly lower in all the 
trimesters compared to nonpregnant period(see table 3) 
 






TC:HDL-C 2.56 3.37 3.90 3.29 
LDL-C:HDL-C 1.44 1.95 2.37 1.79 
TGs:HDL-C 0.56 0.79 1.16 0.64 
VLDL-TGs:CL 1.64±1.53 2.47±3.91 2.57±3.60 3.69±3.48 
LDL-TG:CL 0.46± 1.24±2.68 0.56±0.29 0.14±0.08 
HDL-TG:CL 0.58±0.21 0.60±0.19 0.69±0.32 0.21±0.09 
HDL-TG:ApoA-1 4.09±1.55 5.24±1.43 6.13±1.28 2.73±0.71 
LDL-CL:ApoB 2230±339 2222±228 2113±305 2506±167 
LDL-TG:ApoB 217±59 256±41 332±60 157±32 
LDL-PL:ApoB 748±123 753±66 727±109 824±64 
IDL-TG:ApoB 2026±1085 1666±360 1550±202 1530±371 
VLDL-
TG:ApoB 
6272±1924 6278±1629 5551±1416 7040±2778 
Table 3. Lipid and lipoprotein ratios in the three trimesters of normal pregnancy. 
Taken together, and as shown in table 3, although one of the consequences of pregnancy is 
that maternal lipid metabolism is specifically altered, using the lipid and lipoprotein ratios, 
the hyperlipidaemia occurring in the later part of pregnancy appears to be a balanced 
hyperlipidaemia. These are discussed below 
During the course of normal pregnancy, plasma TGs and cholesterol rise by 200-400% and 
25-50% respectively. The total LDL mass increased during gestation (median concentration 
increased by about 70%, 200-353mg/dl) between 10 to 35weeks, see table 4. The lipid become 
enriched with TGs and depleted in cholesterol. The larger, more buoyant subclasses of LDL 
(LDL-1 and LDL-2) predominant in healthy pregnant females and may in the reproductive 
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age, whereas smaller, denser LDL-3 often occur after menopause [11, 72]. Several studies 
showed there to be an association between elevated plasma TG concentrations, small, dense 
LDL [11, 73] and decreased HDL cholesterol [74], in particular HDL-2 cholesterol [73] 
 
VARIABLES 
10 WEEKS OF 
GESTATION 
35 WEEKS OF 
GESTATION 
Triglyceride(mean) 69.65mg/dl 227.69mg/dl 
Total cholesterol(mean) 172.57mg/dl 282.38mg/dl 
HDL-C(mean) 64.73mg/dl 65.50mg/dl 
VLDL-1(mean) 19mg/dl 109mg/dl 
VLDL-2(mean) 17mg/dl 103mg/dl 
IDL(mean) 26mg/dl 124mg/dl 
LDL 200mg/dl 333mg/dl 
LDL-1 33mg/dl 67mg/dl 
LDL-11 143mg/dl 201mg/dl 
LDL-111 28mg/dl 123mg/dl 
LDL-1 17% of total LDL 20% of total LDL 
LDL-11 69% of total LDL 49% of total LDL 
LDL-111 14% of total LDL 32% of total LDL 
Table 4. Magnitude of changes in lipid and liporpotein values from first to third trimester. 
In men and nonpregnant females, plasma TG is the major determinant of small, dense LDL, 
occurring for 40-60% of the variability of this fraction in the plasma [71,75,76]. In addition, 
recent cross-sectional studies [70,74] have prompted the suggestion that, within the 
relationship between plasma TGs and LDL subfractions profile, there is a threshold effect. 
At low-normal plasma TG concentrations, there is a positive association between LDL-2(the 
major LDL species) concentration and plasma TGs. Above a certain plasma value, 
however(reportedly about 1.5mmol/L in men)[71,75], LDL-2 concentration correlates 
negatively with plasma TGs, and LDL-3 concentration which had been relatively constant 
below this TG concentrations, correlates positively with plasma TG. Generally, percent LDL-
3(and LDL-3 mass) changed little in early gestation despite increasing TG concentrations. 
However, there appeared to be considerable variation between individuals in the gestational 
age and plasma TGs intervals at which change in the LDL profile first manifested—the 
elevated TG levels already present in the first trimester may be responsible for the increased 
in dense LDL 
In line with the alarming observations in LDL subclasses and total LDL mass, LDL-1 mass 
increased around 2-fold, from 33 to 67mg/dl; LDL-2 mass increased least by around 40% 
from a median of 143 to 201mg/dl, reaching a maximum of 218mg/dl at 30weeks gestation, 
whereas in sharp contrast, LDL-3 mass increased by greater than 4-fold from 23 to 123mg/dl. 
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However, as concentration of LDL-2 is declining, that of LDL-3 is increasing and implying 
that the ratio may tend towards a unit. 
Towards end of second trimester to end of gestation, the concentrations of VLDL, IDL, and 
LDL-1/LDL-2 further increased, producing a distribution of lipoproteins dominated by 
buoyant lipoprotein species, in particular LDL-1. In line with this, Winkler’s[11], et al data do 
not support the idea that the same mechanisms as those described for the atherogenic 
lipoprotein phenotypes govern lipid metabolism in late pregnancy.  Therefore, in 
uncomplicated pregnancy there appears to be a balance between potentially damaging factors 
such as altered lipid metabolism and as yet poorly understood protective mechanisms 
[11,33,75]. However, the clinical significance of gestational lipoprotein metabolisms may arise 
if this balance is compromised as in hypertensive disorders of pregnancy. It is in these 
circumstances then when the application of these ratios is very important, for example; Toescu, 
[77] et al while comparing lipid levels between pregnant diabetic women(types 1 and 2 and 
GDM) and pregnant nondiabetic counterparts did not demonstrated any significant 
differences among the groups according to trimesters, implying that the observed 
hyperlipoproteinaemia during pregnancy is independent of diabetes status[10] 
Kilby,[78] et al although observed higher lipid levels and increased in TC, TGs, VLDL/LDL 
ratio, HDL-C with gestational age in type 1 DM, similarly found no significant difference 
from gestationally matched controls[78] in their study. Investigations are required to 
characterize lipid and lipoprotein profile using ratios in the other modulators, particular 
these will assists clinicians while dealing with hyperlipidaemia of pregnancy considering 
the limited quantification opportunities. 
Currently the applications of lipid and lipoprotein ratios in interpreting the hyperlipidaemia 
of pregnancy are limited particularly in the poor developing nations. In spite of the fact that 
the hyperlipidaemia of pregnancy is usually considered physiological, serum lipid and 
lipoprotein levels in pregnancies are generally modulated by complex interactions between 
genetics, medical complications of pregnancy, co-existing medical conditions and other 
maternal factors[19], table 5.  
Therefore the hyperlipidaemia during pregnancy could be classified according to clinical 
implications and future prospects as in fig 1, particularly where there is limited opportunity 
of investigations do to poverty. 
In our laboratory [79] the ratios were found to be important particularly where 
measurement of lipid and lipoprotein is not routinely done due to poverty. In addition 
hyperlipidaemia in pregnancy is confounded by other conditions that may predispose to 
hyperlipidaemia, such as obesity, diabetes mellitus, chronic renal insufficiency, and pre-
eclampsia. Similarly subfractions of lipoproteins are usually not done due to limited 
methodology. Without the use of lipid and lipoprotein ratios particularly considering these 
confounding conditions which are also likely to present with hyperlipidaemia, interpreting 
the hyperlipidaemia of pregnancy is encountered with difficulties. 
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Medical complications of pregnancy
1. Pre-eclampsia 
2. Pregnancy-induced hypertension 
3. Gestational diabetes mellitus 
4. Intra-uterine growth restriction(retardation) 
5. Prelipaemia 
Co-existing medical conditions 
1. Obesity 
2. Types 1 and 2 diabetes mellitus 
3. Hypothyroidism 
4. Hypertension 
5. Renal diseases, particularly nephritic syndrome 
6. Alcoholism 
7. Medications, eg LMWt-heparin and glucocorticoid 
Other maternal factors 
1. BMI(Obesity) 
2. Maternal weight gain in the index pregnancy 
3. Maternal nutrition 
4. Pre-pregnancy lipid levels 
Table 5. Factors that can also modulate lipid and lipoprotein concentrations in pregnancy (genetic 




Figure 1. Classification of hyperlipidaemia of pregnancy 
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Whilst the hyperlipidaemia of pregnancy is considered physiological, studies have 
demonstrated that deviations present as a two-edged sword. On one hand, development of 
the physiological hyperlipidaemia out of proportion could be associated with many 
consequences and on the other hand failure to development the required proportion of 
physiological hyperlipidaemia of pregnancy could also be associated with some 
consequences, Table 6 and these will be discussed subsequently 
 
Consequences of hyperlipidaemia






Unanswered questions concerning hyperlipidaemia of pregnancy 
Is hyperlipidaemia of pregnancy atherogenic? 
Is hyperlipidaemia of pregnancy a dyslipidaemia? 
Future effect of pregnancy-induced Supraphysiologic hyperlipidaemia 
Pre-eclapmsia and hyperlipidaemia of pregnancy 
 
Consequences of failure of development of hyperlipidaemia
IUGR—Intra-uterine growth retardation
Future development of metabolic syndrome in affected fetus
Table 6. Consequences of deviations of Hyperlipidaemia of pregnancy. 
6. Is normal pregnancy atherogenic?[80] 
The change in triglycerides in normal pregnancy is important in relation to lipoprotein 
subclasses, such as LDL. These lipoproteins contain subfractions of various sizes, densities 
and compositions, which differ in their ability to initiate atherogenesis [81]. One of the 
subfractions of LDL (LDL-3) is small, dense LDL particles which do not bind readily to the 
LDL receptors and therefore remain in the circulation for longer time,  penetrate the arterial 
intima better than do larger ones[82] and are more readily oxidized, probably because they 
contain less vitamin E and other antioxidants[83]. Finally, their uptake into macrophages to 
create form cells, and initiate atherogenesis, is facilitated [84]. This may explain their 
identification as an independent risk factor for coronary heart disease [82-84]. 
Plasma triglycerides are the major determinant of small, dense LDLs, accounting for 40-60% 
of the variability of this fraction in the plasma [75]. VLDL represents the major precursor of 
LDL and reflects plasma TGs levels. Two subclasses of VLDL have been defined: a large and 
buoyant fraction enriched with TGs (VLDL-1) and a smaller, denser fraction(VLDL-2). It 
follows from the association between LDL subclasses and raised TGs that VLDL-1 may be 
important as a vehicle in the process of neutral lipid exchange and generation of small, 
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dense LDLs. Cholesterol esters are transferred from LDL and HDL to VLDL-1 by cholesterol 
ester transfer protein(CETP) in exchange for TGs and the increased concentration of VLDL-
1, due to hypersecretion by the liver promote TG transfer into LDL during pregnancy[33]. 
TG-enriched LDL particles subsequently undergo a size reduction through the action of 
hepatic lipase, resulting in the formation of small, dense LDL subfractions. In addition 
Lippi[2], et al demonstrated in their study that advanced pregnancy is associated with an 
increased prevalence of undesirable or abnormal values for total cholesterol, LDL-C and 
TGs in the second trimester, and total cholesterol, LDL-C, TGs TC:HDL ratio in third 
trimester demonstrating that physiological pregnancy is associated with a substantial 
modification of lipid and lipoproteins metabolism from the second trimester, providing 
reference ranges for traditional and emerging cardiovascular risk predictors throughout the 
gestational period. Therefore, is normal pregnancy atherogenic? 
All pregnant women develop a transient hyperlipidaemia associated with 
hypertriglyceridaemia, and subsequent formation of small, dense LDL particles, both of 
which are an independent risk factor for CHD, and by 3rd trimester most women have a 
lipid profile which would be considered highly atherogenic in the non-pregnant state[13]. 
Increased prevalence of angina, cholesterol gallstone, and obesity in postmenopausal 
women who have had several pregnancies has been observed [85]. Yet the long-term 
consequences of multiple pregnancy, gestational diabetes or maternal obesity in LDL 
subfractions and lipid profile are unknown. Further studies are recommended to determine 
if certain women are at increased risk of CVD in later life because of effects on their lipid 
profile during pregnancy. In contrast, increasing suggestions are that maternal 
hypercholesterolaemia during pregnancy even when temporary and limited to pregnancy 
triggers pathogenic events in the fetal aorta,  greatly enhanced fatty streak formation and 
that may influence atherogenesis later in life[14,15].  Fetal plasma cholesterol levels are high 
and are proportional to the maternal cholesterol levels [14] in second trimester, decline with 
increasing fetal age[14] and are even lower at term birth. This is supported by the fact that 
lipid levels observed in umbilical cord blood(UCB) from normal pregnancy were 
significantly lower than those found in maternal blood with exception of HDL-C, and that 
LDL:HDL ratio in neonate of normal pregnancy are much lower than the value in normal 
pregnant mothers[16]. The high HDL levels and a lower LDL:HDL ratio in UCB suggest that 
the fetus of a normal pregnancy is protected against atherogenic lipoprotein[16]. Despite 
these findings, studies at autopsy demonstrated that atherosclerosis progresses much faster 
in offsprings of hypercholesterolaemic mother than in offsprings of normocholesterolaemic 
mothers[86]. Same studies observed that at each time point, offsprings of 
hypercholesterolaemic mothers had 1.5 to 3-fold larger lesions than offsprings of 
normocholesterolaemic mothers, and they suggested that, pathogenic programming in utero 
increases the susceptibility to atherogenic risk factors later in life and maternal intervention 
with cholesterol-lowering agents reduce postnatal lipid peroxidation and atherosclerosis in 
their offsprings[87]. A registry study by Toleikyte,[22] et al, of heterozygous familial 
hypercholesterolaemic(FH) mothers observed that: the serum levels of cholesterol in the 
nonpregnant, nontreated women were 370mg/dl(9.59mmol/L); no maternal cardiovascular 
deaths were observed; the children of mothers with FH were no more likely than the general 
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population to be born prematurely, have low birth weight, or have congenital 
malformations; and that no congenital malformations were observed in the 19 pregnancies 
associated with the use of lipid-lowering drugs during pregnancy. However, the current 
trend is that Statins, classified by FDA as category X in pregnancy, should be avoided in 
pregnancy [23,24]. Although there are observations for and against the maternal 
hyperlipidaemia being atherogenic to the fetus and increasing tendencies of future 
atherosclerosis, a long-term follow-up studies of offsprings of mothers with FH who did not 
inherited the disease is recommended. The result will demonstrate evidence of effects of 
maternal hyperlipidaemia on fetal atherosclerosis and or predisposition to future 
atherosclerosis in these offsprings.  
6.1. Fetal lipoproteins in pre-eclampsia 
Successful placental development is very important for normal fetal growth, and may 
condition health and well being during childhood and even adulthood [88], because it forms 
the interface for nutrients, fluids and gas exchange between mother and fetus. Pre-eclampsia 
(PE), a human pregnancy specific vascular disorder, defines a pathologic condition that 
affects the mother and can adversely influence the feto-placental unit. PE is associated with 
placental dysfunction, oxidative stress[1, 89], dyslipidaemia[16,90] and endothelial cell 
activation, and is a major cause of maternal and fetal morbidity and mortality[88] A pro-
atherogenic lipid profile, characterized by increased TG levels with reduced HDL 
concentration[90, 91] and increased small, dense LDL particles[90] has been described. In 
contrast other studies demonstrated a dominance of buoyant LDL-1 and a significant 
decreased of small, dense LDL, namely LDL-5 and LDL-6[92]. Notwithstanding, it has been 
suggested that an abnormal lipid metabolism may not only be a manifestation of PE, but 
dyslipidaemia may play an essential role in its pathogenesis 
Apart from genetic predisposition, the second group of disorders associated with an 
increased risk of PE includes a variety of chronic conditions such as dyslipidaemia, diabetes 
mellitus, hypertension, renal diseases, and various thrombophilias[93]. These disorders can 
be convincingly grouped together based on their common association with vascular 
endothelial dysfunction, especially those which have been included in the proposed 
metabolic syndrome [93]. Ironically also all are associated with dyslipidaemia. Although PE 
is a multifactorial disorder, it is therefore tempting to ask, could dyslipidaemia be the 
central focal point linking these disorders into pathogenesis of PE? One of the abnormalities 
found in the abnormal placental bed is presence of acute atherosis in desidual vessels, 
characterized by accumulations of foam cells and perivascular mononuclear cell infiltration. 
Reduced placental perfusion and placental/fetal hypoxia may develop. 
Catarino[16], et al, while comparing lipid and lipoproteins in normal pregnant and PE 
pregnant women found an enhanced physiologic hyperlipidaemia. However, the most 
striking difference noted in PE women was the rise TGs that almost double the median 
value compared to normal pregnant women. Higher TGs value has been associated with 
endothelial dysfunction and may therefore play an important role in the pathogenesis of PE. 
Considering the placental dysfunction and lipid changes occurring in PE, fetal lipid 
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metabolism can be affected due to an altered placental transfer of lipids. Maternal TGs does 
not cross the placenta. It has to be hydrolyzed by human placental LPL into FFAs which is 
then transported to the fetus. Fetal TG levels are therefore dependent on maternal TGs. 
Moreover, the placenta also contains receptors for VLDL, LDL and HDL which also 
transport TGs and other esterified lipid to the fetus (23) 
Catarino[16],et al observed that lipid levels observed in umbilical cord blood (UCB) from 
normal pregnancy were significantly lower than those found in maternal blood except for 
HDL, which was similar. In addition, LDL:HDL ratio in neonates of normal pregnancies are 
much lower than the values in normal pregnant mothers. In contrast, lower values of HDL 
and ApoA-1 and higher TG levels were noted in neonates of PE mothers. In addition, higher 
LDL:HDL ratio, a decreased HDL which is more pronounced than ApoA-1, suggest that 
fetal loading of ApoA-1 with cholesterol is significantly less in PE. Hence fetal HDL 
composition is likely to be altered due possibly to enrichment with the enhanced 
hypertriglyceridaemia. Also observed in the PE is a significantly higher value of TGs in UCB 
which is parallel with significant increased TGs in maternal blood. Since 
hypertriglyceridaemia is considered a maternal adaptation in order to assure fetal growth in 
normal pregnancy, the exaggerated hypertriglycedaemia noticed in PE mothers could be a 
compensation pathway to face the uteroplacental hypoperfusion in order to enhance FAs 
transfer to the fetus. In line with this, it seems LPL expression is also enhanced in PE as was 
observed in IUGR [94]. Taken together, it appears lipid transfer from maternal side in PE 
mothers to their fetus are altered in both quantity and quality and does not seems to be 
protective as noticed in neonates of normal pregnancies. In support of this PE has been 
associated with reduced fetal birth weight [95, 96] and the expression of lipoprotein 
receptors are decreased in the placenta of women with PE. 
PE pregnancies is associated with an enhanced hypertriglyceridaemia, which seems to have 
a negative impact on fetal lipid profile, as reflected by a higher atherogenic LDL:HDL ratio, 
decreased HDL, disproportionate decreased in HDL and ApoA-1 and enhanced 
hypertriglycedaemia, children born in pregnancies associated with PE deserve a closer 
clinical follow-up later in life. 
6.2. Role of lipid metabolism in pathogenesis of intrauterine growth restriction 
(IUGR)[17] 
It was proposed that the abnormal lipid metabolism noted in pre-eclampsia was in an attempt 
to compensate for the placental insufficiency [97], given the physiological role of gestational 
hyperlipidaemia in supplying both cholesterol and triglycerides to the rapidly developing fetus 
[98]. In contrast Dabi[17], et al demonstrated that concentration of total cholesterol (TC), TGs, 
LDL and VLDL observed to increase with increasing gestational age in normal pregnancies, 
these lipids and lipoproteins decreased with increasing gestational age in pregnancies with 
IUGR. HDL did not change significantly. These findings certainly indicated that pregnancies 
complicated by IUGR are associated with an abnormal lipid profile, particularly decreased 
levels of TC, TGs, LDL and HDL(Dabi [17],et al Sattar[18], et al), see table 7 
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  Group A Group B  
        
Weeks 
 
28-31 32-36 37-40  28-31 32-36 37-40 
TC 216.3+29.2 202.5+26.0 191.5+34.5  238.0+17.0 250.7+27.6 260.3+23.6 
TGs 173.83+78.18 168.23+51.73 137.83+18.25  148.25+15.31 160.36+24.43 171.14+41.56 
HDL-C 42.0+5.3 43.0+4.4 46.4+3.2  44.4+4.5 43.0+6.0 41.6+8.2 
LDL 139.4+23.9 126.3+21.8 117.0+31.8  165.9+26.5 174.8+26.5 184.5+23.4 
VLDL 34.78+15.63 33.64+10.34 27.26+3.81  29.77+3.06 32.05+4.91 34.22+8.31 
Table 7. Lipid and Lipoprotein changes with advancing gestational age(Group A=Pts with IUGR and 
Group B=Pt with normal pregnancy) 
It is well known that normal fetal development needs the availability of both essential fatty 
acids and long chain polyunsaturated fatty acids (LCPUFAs), thus making a persuasive case 
indicating a relationship between nutritional status of mother during gestation reflecting her 
lipid profile and fetal growth. From observations in study by Dabi[17], et al and similar 
findings in other studies, it is possible that the decreased concentrations of TC, TGs, VLDL 
and LDL may have decreased availability of glycerol, LCPUFAs and essential fatty acids to 
the fetuses of mothers with otherwise normal pregnancy ultimately leading to IUGR. In 
addition to above findings, Sattar[18], et al observed a decreased in levels of VLDL-2 and 
IDL in IUGR pregnancies, which are precursors of LDL. Taken together, the decreased 
cholesterol levels (mainly reflected as decrease LDL) may be due to decreased synthesis of 
LDL in women with IUGR. The HDL: apoA and apoB:apoA ratios were found to be higher 
in the IUGR and was suggested that blood lipid modifications in the IUGR group are partly 
secondary to changes in HDL metabolism and the competitive inhibition of fibrinolysis by 
apoB which is increased in pregnancy with IUGR. This indicated that apoA: apoB ratio 
could be a good marker for the early detection of IUGR. Taken together also, these findings 
definitely generated considerable interest in certain aspects of fetal growth and its 
relationship to blood lipid levels during pregnancy. However, more study is recommended 
aiming at analyzing the otherwise normal pregnancies associated with IUGR, particularly to 
elucidate the hypothesis that the decrease in TGs(and particularly LDL and VLDL-2) 
compromises the supply of substrates for energy production to the growing fetus resulting 
in IUGR. The effect of the changes in lipid profile and its translation in changes in blood 
viscosity needs more extensive research including detailed analyses of apoA and apoB 
levels in these patients.  
6.3. Pregnancy-induced Supraphysiologic hyperlipidaemia 
It is well known in literature that hyperlipidaemia is a normal metabolic adjustment in 
pregnancy benefiting both mother and the fetus. However, some women may not be able to 
adapt to the hyperlipidaemic stress of pregnancy. In addition, in similarity with other 
gestational metabolic syndromes such as gestational diabetes mellitus (GDM), pregnancy-
induced hypertension (PIH), pre-eclampsia, eclampsia, etc, some of them may develop a 
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state of Supraphysiologic hyperlipidaemia, defined as lipid levels greater than 95th 
percentile for the corresponding gestational age, because of failed adaptation to requirement 
of pregnancy. Supraphysiologic hyperlipidaemia may serve as a marker for what is cited by 
Montes[99], et al, a ‘prelipaemia’ in the same way that GDM is a marker for pre-diabetes. 
The characteristics of Supraphysiologic hyperlipidaemia, as observed by Montes[99], et al, 
are that, the antepartum hyperlipidaemia may return to normal levels postpartum more 
slowly than normal, the presence of HDL cholesterol concentrations that are persistently 
low antepartum and postpartum, and the patients do have hyperlipidaemic family 
members. In contrast, hypercholesterolemia is not greatly exaggerated in pregnancy among 
these women. Are there future consequences of the pregnancy-induced Supraphysiologic 
hyperlipidaemia? Long-term follow-up studies of women with genetically well-
characterized disorders of lipoprotein metabolism are required to determine if an abnormal 
lipoprotein response in pregnancy can identify prelipaemic subjects and distinguish among 
the major disorders of lipoprotein metabolism. Identification of the prelipaemia will provide 
an opportunity to study prospectively the natural progression, potential for atherosclerosis, 
and possible treatment of hyperlipidaemia from early adulthood. 
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